Summary
- Profile Type
- Technology offer
- POD Reference
- TOGR20250623015
- Term of Validity
- 23 June 2025 - 23 June 2026
- Company's Country
- Greece
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- An advanced academic lab in Greece specializing in pediatric immunology, host-pathogen interactions and vaccine development offers its range of diagnostic and related services to biotech/SMEs, pharma, and academic institutions working on antigen and biomarker discovery, the development of immunoassays and preclinical and post-licensure vaccine evaluation, through a commercial agreement with technical assistance or a research cooperation agreement.
- Full Description
-
A leading translational research unit based in one of the largest pediatric hospitals in Greece is dedicated to advancing the fields of immunology and vaccinology through cutting-edge research and clinical integration.
With over 20 years of expertise in pediatric vaccine immunology, the unit’s lab supports the full spectrum of vaccine development — from early-stage immune profiling and antigen evaluation to Phase 1–3 clinical trials and post-licensure surveillance. The lab is uniquely positioned to access pediatric patient samples, including immunocompromised populations (e.g., BMT, HIV, congenital hemoglobinopathies), ensuring real-world applicability and ethical compliance.
Key Research Areas:
• Detailed evaluation of vaccine-induced immune Responses
Designing customized assays to measure vaccine-induced immunity, assessing immune biomarkers (cytokines, chemokines, transcriptomics), and identifying immunological correlates of protective vaccine responses
• Pediatric Clinical Trials in healthy and immunocompromised paediatric populations
Supporting Phase 1–3 trials, offering protocol development, sample collection, immune monitoring, and data analysis in full compliance with GDPR and pediatric ethical standards.
• Full clinical integration within a leading pediatric hospital with proven access to immunocompromised pediatric populations.
• Translational Research & Precision Vaccinology
Using omics, multiplex assays, and big data analytics to study pediatric infectious diseases and develop precision vaccinology strategies.
Scientific Capabilities:
1. Customized Immunological Assays
• Development of ELISA, ELISPOT, Luminex, Flow Cytometry, and Olink-based assays
• Assay optimization for novel antigens, delivery platforms, and emerging pathogens
2. Immune Response Profiling
• Quantification of antigen-specific antibodies (total IgG, subclasses, isotypes)
• Cytokine and chemokine measurement to assess Th1/Th2 response balance
• Functional assays: ADCC, MOPA
• T-cell activation and B-memory cell analysis for immunological memory evaluation
3. Areas of Expertise
• Preclinical Vaccine Development across mRNA, protein sub-unit, viral vector, and sVLP platforms
• Vaccine Safety Assessment by identifying inflammatory and adverse response biomarkers
• Immune Correlates of Protection, linking lab data with real-world vaccine outcomes
4. Biomarker Discovery & Precision Medicine
• Identifying biomarkers to evaluate host-pathogen interactions
• Applying proteomic and transcriptomic profiling for responder/non-responder differentiation
• Supporting personalized immunization strategies
Clinical Applications:
Tracking records in early- to late-phase clinical trials and post-marketing evaluations.
Phase 1/2/3 Clinical Trials: Cellular and humoral immune monitoring tailored to diverse formulations, schedules, and populations.
Post-Licensure Evaluation: Longitudinal immune response tracking, adverse event monitoring, and correlates of protection refinement in general and high-risk pediatric groups.
The Greek lab seeks SMEs, biotech or pharmaceutical companies who could benefit from the above services through a commercial agreement with technical assistance. They are also sought, together with academic and clinical partners, to participate in relevant calls for proposals in National or EU funding programmes through a research cooperation agreement. - Advantages and Innovations
-
Advanced Immunoassay Development:
• Custom ELISA, ELISPOT, FACS access to Luminex and Olink platforms
• Functional antibody assays (e.g., ADCC, MOPA)
• Immune memory profiling (B- and T-cell assays)
Technology Readiness Level (TRL) 4–6:
Validated lab assays, ready for preclinical and early clinical research collaborations. Assay platforms adaptable to industry validation needs
Biomarker discovery
• Biomarker identification by immune mapping of host-pathogen interactions
Clinical Trial Partnerships:
Proven clinical integration to healthy and immunocompromised paediatric populations followed up in a leading Greek paediatric hospital. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- No IPR applied
Partner Sought
- Expected Role of a Partner
-
Academic and clinical partners are welcomed for joint research proposals, particularly under Horizon Europe, IHI (Innovative Health Initiative), and other national or EU funding calls. Partners could be involved in research in infectious diseases, their association with non-communicable diseases, immunological signatures of host-pathogen interactions and biomarker discovery, with a particular focus on pediatric populations, both healthy and immunocompromised.
The Greek lab is also especially interested in cooperating through commercial or research cooperation agreements with SMEs, biotech companies and pharmaceutical companies in the fields of vaccinology, diagnostics, and immunology related to infectious diseases.
Biotech SMEs involved in the development of diagnostic immunoassays, particularly immune-based tests, are sought. The Greek lab could provide assistance in assay development, optimization, and the clinical validation of novel diagnostics.
The Greek lab also aims to collaborate with experts in systems biology, multi-omics, or computational analyses that focus on identifying immune signatures associated with disease progression or protection.
Potential partners could also be pharamceutical companies evaluating vaccine-induced immune responses in different populations, using a wide range of correlates of protection and data modeling. By providing them with a customized range of traditional and novel immunological markers such as antibodies, T-cell responses, memory B cells, and innate immunity indicators, the Greek lab could support all stages of vaccine evaluation, from clinical development to post-licensure evaluation.
The Greek lab is also interested in collaborating with pharmaceutical companies performing immunobridging studies where the Greek lab could advise on data interpretation and give regulatory insight.
In summary, the Greek lab is particularly interested in cooperating with:
• Academic or clinical partners for collaborative research proposals to participate in National and European calls for funding (Horizon Europe, IHI, etc.)
• SMEs, biotech, or pharmaceutical companies involved in:
o Vaccine R&D
o Novel antigen discovery
o Biomarker-based diagnostics
o Peclinical and post licensure vaccine evaluation.
The collaboration may involve joint R&D, technology exchange, participation in multi-partner research projects, or contribution to clinical protocols.
Through the EEN platform, the Greek lab aims to create a dynamic, interdisciplinary network supporting the advancement of immunological tools, vaccine innovation and diagnostics. - Type and Size of Partner
- SME 11-49
- University
- SME 50 - 249
- R&D Institution
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- 06001002 - Clinical Research, Trials
- 06001006 - Human vaccines
- Market keywords
- 05006 - Anatomy, Pathology, Immunology, Physiology
- 05001001 - Diagnostic services
- Sector Groups Involved
- Digital
- Health
- Targeted countries
- All countries